Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomes

References

• Aidasani D, Zaya MJ, Malpas PB, Locuson CW. (2008). In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition. Drug Metab Dispos 36:1512–18.
   PubMed Web of Science ®Google Scholar
• Alberola J, Perez Y, Puigdemont A, Arboix M. (1993). Effect of age on theophylline pharmacokinetics in dogs. Am J Vet Res 54:1112–15.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Moro AR, Percudani M. (1994). Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26:201–14.
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners JO, Veronese ME, et al. (1993). Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521–30.
   PubMed Web of Science ®Google Scholar
• Arsenault WG, Boothe DM, Gordon SG, et al. (2005). Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. Am J Vet Res 66:2172–6.
   PubMed Web of Science ®Google Scholar
• Ascenzi P, Fanalo G, Fasano M, et al. (2014). Clinical Relevance of Drug Binding to Plasma Proteins. J Mol Struct 1077:4–13.
   Web of Science ®Google Scholar
• Austin RP, Barton P, Cockroft SL, et al. (2002). The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497–503.
   PubMed Web of Science ®Google Scholar
• Bell ET, Devi JL, Chiu S, et al. (2016). The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs. J Vet Pharmacol Ther 39:54–61.
   PubMed Web of Science ®Google Scholar
• Benchaoui HA, Cox SR, Schneider RP, et al. (2007). The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther 30:336–44.
   PubMed Web of Science ®Google Scholar
• Blaisdell J, Goldstein JA, Bai SA. (1998). Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26:278–83.
   PubMed Web of Science ®Google Scholar
• Boothe DM. (2012). Principles of drug therapy. 2nd ed. Philadelphia, PA: Saunders.
   Google Scholar
• Boxenbaum H. (1980). Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8:165–76.
   PubMedGoogle Scholar
• Boxenbaum H. (1982). Comparative pharmacokinetics of benzodiazepines in dog and man. J Pharmacokinet Biopharm 10:411–26.
   PubMedGoogle Scholar
• Chao P, Uss AS, Cheng K. (2010). Use of intrinsic clearance for prediction of human hepatic clearance. Expert Opin Drug Metab Toxicol 6:189–98.
   PubMed Web of Science ®Google Scholar
• Colclough N, Ruston L, Wood JM, Macfaul PA. (2014). Species differences in drug plasma protein binding. MedChemComm 5:963–7.
   Web of Science ®Google Scholar
• Cotler S, Gustafson JH, Colburn WA. (1984). Pharmacokinetics of diazepam and nordiazepam in the cat. J Pharm Sci 73:348–51.
   PubMed Web of Science ®Google Scholar
• Court MH. (2013). Canine Cytochrome P-450 pharmacogenetics. Vet Clin North Am Small Anim Pract 43:1027–38.
   PubMed Web of Science ®Google Scholar
• D'mello A, Venkataramanan R, Satake M, et al. (1989). Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. Res Commun Chem Pathol Pharmacol 64:441–54.
   PubMedGoogle Scholar
• Dahl ML, Iselius L, Alm C, et al. (1993). Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur J Clin Pharmacol 44:445–50.
   PubMed Web of Science ®Google Scholar
• Dennison JB, Kulanthaivel P, Barbuch RJ, et al. (2006). Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317–27.
   PubMed Web of Science ®Google Scholar
• Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. (1995). Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225–30.
   PubMed Web of Science ®Google Scholar
• Durtschi AL, Gompf RE, Martin-Jimenez T, et al. (2011). Pharmacokinetics and bioavailability of carvedilol in catsed. Denver (CO): ACVIM Forum.
   Google Scholar
• Emoto C, Iwasaki K. (2009). Approach to predict the controbiution of cytochrome P450 enzymes to drug metablism in the early drug-discovery stage: the effect of the expression of cytochrome b5 with recombinant P450 enzymes. Xenobiotica 37:986–99.
   Web of Science ®Google Scholar
• Giorgi M, Yun H. (2012). Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. J Vet Sci 192:239–41.
   Google Scholar
• Gorski JC, Jones DR, Hamman MA, et al. (1999). Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931–44.
   PubMed Web of Science ®Google Scholar
• Greenway CV, Stark RD. (1971). Hepatic vascular bed. Physiol Rev 51:23–65.
   PubMed Web of Science ®Google Scholar
• Hanzlicek AS, Gehring R, Kukanich B, et al. (2012). Pharmacokinetics of oral pimobendan in healthy cats. J Vet Cardiol 14:489–96.
   PubMed Web of Science ®Google Scholar
• Heikkinen AT, Friedlein A, Matondo M, et al. (2015). Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine. Pharm Res 32:74–90.
   PubMed Web of Science ®Google Scholar
• Hickman M, Cox S, Mahabir S, et al. (2008). Safety, pharmacokinetics and use of the novel NK‐1 receptor antagonist maropitant (CereniaTM) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 31:220–9.
   PubMed Web of Science ®Google Scholar
• Jones HM, Houston JB. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973–82.
   PubMed Web of Science ®Google Scholar
• Kato R. (1966). Possible role of P-450 in the oxidation of drugs in liver microsomes. J Biochem 59:574–83.
   PubMed Web of Science ®Google Scholar
• Kim KA, Chung J, Jung DH, Park JY. (2004). Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 60:575–81.
   PubMed Web of Science ®Google Scholar
• King JN, Maurer MP, Hotz RP, Fisch RD. (2000). Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. Am J Vet Res 61:74–9.
   PubMed Web of Science ®Google Scholar
• Komura H, Kawase A, Iwaki M. (2005). Application of substrate depletion assay for early prediction of nonlinear pharmacokinetics in drug discovery: assessment of nonlinearity of metoprolol, timolol, and propranolol. J Pharm Sci 94:2656–66.
   PubMed Web of Science ®Google Scholar
• Kuepfer L, Niederalt C, Wendl T, et al. (2016). Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol 5:516–31.
   PubMedGoogle Scholar
• Kung K, Riond JL, Wanner M. (1993). Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 16:462–8.
   PubMed Web of Science ®Google Scholar
• Kuriya S, Ohmori S, Hino M, et al. (2000). Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes. Drug Metab Dispos 28:73–8.
   PubMed Web of Science ®Google Scholar
• Lainesse C, Frank D, Meucci V, et al. (2006). Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. J Vet Pharmacol Ther 29:271–8.
   PubMed Web of Science ®Google Scholar
• Larson JA. (1963). Elimination of glycerol as a measure of hepatic blood flow in the Cat. Acta Physiol 57:224–34.
   Web of Science ®Google Scholar
• Lebkowska-Wieruszewska B, Barsotti G, Lisowski A, et al. (2017). Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. N Z Vet J 65:19–23.
   PubMed Web of Science ®Google Scholar
• Li X-Q, Björkman A, Andersson T, et al. (2003). Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–42.
   PubMed Web of Science ®Google Scholar
• Livezey MR, Briggs ED, Bolles AK, et al. (2014). Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica 44:309–19.
   PubMed Web of Science ®Google Scholar
• Locuson C, Williams P, Adcock J, Daniels J. (2016). Evaluation of tizanidine as a marker of canine CYP1A2 activity. J Vet Pharmacol Ther 39:122–30.
   PubMed Web of Science ®Google Scholar
• Lu P, Singh SB, Carr BA, et al. (2005). Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J Pharmacol Exp Ther 313:518–28.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76:391–6.
   PubMed Web of Science ®Google Scholar
• Mandour ME, El Turabi H, Homeida MM, et al. (1990). Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 84:389–93.
   PubMed Web of Science ®Google Scholar
• Mehl ML, Kyles AE, Craigmill AL, et al. (2003). Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. J Vet Pharmacol Ther 26:349–54.
   PubMed Web of Science ®Google Scholar
• Mehrota N, Gupta M, Kovar A, Meibohm B. (2007). The rold of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 19:253–67.
   PubMed Web of Science ®Google Scholar
• Mise M, Hashizume T, Matsumoto S, et al. (2004). Identification of Non-Functional Allelic Variant og CYP1A2 in Dogs. Pharmacogenetics 14:769–73.
   PubMedGoogle Scholar
• Nielsen KK, Flinois JP, Beaune P, Brosen K. (1996). The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277:1659–64.
   PubMed Web of Science ®Google Scholar
• Norkus C, Rankin D, Kukanich B. (2015). Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortryptyline in Greyhound dogs. Vet Anaesth Analg 42:580–9.
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9.
   PubMed Web of Science ®Google Scholar
• Okamatsu G, Komatsu T, Ono Y, et al. (2017). Characterization of feline cytochrome P450 2B6. Xenobiotica 47:93–102.
   PubMed Web of Science ®Google Scholar
• Oldham HG, Clarke SE. (1997). In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R (+)-and S (−)-carvedilol. Drug Metab Dispos 25:970–7.
   PubMed Web of Science ®Google Scholar
• Paine SW, Menochet K, Denton R, et al. (2011). Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net re-absorption. Drug Metab Dispos 39:1008–13.
   PubMed Web of Science ®Google Scholar
• Pan LC, Carpino PA, Lefker BA, et al. (2001). Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue. Endocrine 14:121–32.
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Theoretical considerations of “well-stirred” models and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–53.
   PubMedGoogle Scholar
• Pichette V, Leblond FA. (2003). Drug metabolism in chronic renal failure. Curr Drug Metab 4:91–103.
   PubMed Web of Science ®Google Scholar
• Quimby JM, Gustafson DL, Samber BJ, Lunn KF. (2011). Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. J Vet Pharmacol Ther 34:388–96.
   PubMed Web of Science ®Google Scholar
• Rasool MF, Khalil F, Laer S. (2015). A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet 54:943–62.
   PubMed Web of Science ®Google Scholar
• Regardh CG, Gabrielsson M, Hoffman KJ, et al. (1985). Pharmacokinetics and metabolism of omeprazole in animals and man-an overview. Scand J Gastroenterol Suppl 108:79–94.
   PubMedGoogle Scholar
• Rendic S, Guengerich FP. (2015). Survey of human oxidoreductasees and cytochrome P450 enzymes involved in the metabolism of xenobiotic and naterual chemicals. Chem Res Toxicol 28:38–42.
   PubMed Web of Science ®Google Scholar
• Renton KW. (2004). Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235–43.
   PubMed Web of Science ®Google Scholar
• Richardson PD, Withrington PG. (1981). Liver blood flow. I. Intrinsic and nervous control of liver blood flow. Gastroenterology 81:159–73.
   PubMed Web of Science ®Google Scholar
• Scherr MC, Lourenco GJ, Albuquerque DM, Lima CS. (2011). Polymorphism of cytochrome P450 A2 (CYP1A2) in pure and mixed breed dogs. J Vet Pharmacol Ther 34:184–6.
   PubMed Web of Science ®Google Scholar
• Shah SS, Sanda S, Regmi NL, et al. (2007). Characterization of cytochrome P450-mediated drug metabolism in cats. J Vet Pharmacol Ther 30:422–8.
   PubMed Web of Science ®Google Scholar
• Sikka R, Magauran B, Ulrich A, Shannon M. (2005). Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 12:1227–35.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Deitcher SR. (2013). Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 71:555–64.
   PubMed Web of Science ®Google Scholar
• Smith R, Jones RD, Ballard PG, Griffiths HH. (2008). Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog. Xenobiotica 38:1386–98.
   PubMed Web of Science ®Google Scholar
• Stormer E, Von Moltke LL, Shader RI, Greenblatt DJ. (2000). Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28:1168–75.
   PubMed Web of Science ®Google Scholar
• Sugihara N, Furuno K, Kita N, et al. (1993). The influence of increased plasma protein binding on the disposition of quinidine in turpentine-treated rats. Biol Pharm Bull 16:63–7.
   PubMed Web of Science ®Google Scholar
• Takada K, Arefayene M, Desta Z, et al. (2004). Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50:2202–10.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Shinkyo R, Sakaki T, et al. (2005). Cytochrome P450 2E polymorphism in feline liver. Biochim Biophys Acta 1726:194–205.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Birkett DJ, Veronese ME, et al. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401–7.
   PubMed Web of Science ®Google Scholar
• Tavoloni N. (1985). Postnatal changes in hepatic microsomal enzyme activities in the puppy. Biol Neonate 47:305–16.
   PubMedGoogle Scholar
• Toutain PL, Buosquet-Melou A. (2002). Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther 25:460–3.
   PubMed Web of Science ®Google Scholar
• Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. (1999). Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47:545–52.
   PubMed Web of Science ®Google Scholar
• Trouchon T, Lefebvre S. (2016). A review of enrofloxacin for veterinary use. OJVM 6:40–58.
   Google Scholar
• Van Beusekom CD, Fink-Gremmels J, Schrickx JA. (2013). Comparing the glucuronidation capacity of the feline liver with substrate-specific glucuronidation in dogs. J Vet Pharmacol Ther 37:18–24.
   PubMed Web of Science ®Google Scholar
• Van Beusekom CD, Schipper L, Fink-Gremmels J. (2010). Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. J Vet Pharmacol Ther 33:519–27.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Greenblatt DJ, Von Moltke LL, et al. (1998). Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 38:112–21.
   PubMed Web of Science ®Google Scholar
• Vilmgnyi E, Küng K, Riond JL, et al. (1996). Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles. J Small Anim Pract 37:535–9.
   PubMed Web of Science ®Google Scholar
• Walker DK, Ackland MJ, James GC, et al. (1999). Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29:297–310.
   PubMed Web of Science ®Google Scholar
• Wandel C, Böcker R, Böhrer H, et al. (1994). Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73:658–61.
   PubMed Web of Science ®Google Scholar
• Wang RW, Newton DJ, Scheri TD, Lu AY. (1997). Human Cytochrome P450 3A4-Catalyzed Testosterone 6β-Hydroxylation and ErythromycinN-Demethylation. Drug Metab Dispos 25:502–7.
   PubMed Web of Science ®Google Scholar
• Warrington JS, Shader RI, Von Moltke LL, Greenblatt DJ. (2000). In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28:392–7.
   PubMed Web of Science ®Google Scholar
• Warry E, Hansen RJ, Gustafson DL, Lana SE. (2011). Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma. J Vet Intern Med 25:903–8.
   PubMed Web of Science ®Google Scholar
• Watkins PB. (1990). The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 23:1301–9.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. (1997). Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161–9.
   PubMed Web of Science ®Google Scholar
• Yancey M, Merritt D, Lesman S, et al. (2010). Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.J Vet Pharmacol Ther 33:162–71.
   PubMed Web of Science ®Google Scholar
• Yasumori T, Nagata K, Yang SK, et al. (1993). Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 3:291–301.
   PubMedGoogle Scholar
• Zhang HF, Wang HH, Gao N, et al. (2016). Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes. J Pharmacol Exp Ther 358:83–93.
   PubMed Web of Science ®Google Scholar